Interstitial Cystitis (IC)

Categories: Nephrological diseases, Rare diseases

Aliases & Classifications for Interstitial Cystitis

MalaCards integrated aliases for Interstitial Cystitis:

Name: Interstitial Cystitis 12 73 20 58 36 42 15 17 70 32
Painful Bladder Syndrome 20 58 70
Bladder Pain Syndrome 20 58 70
Interstitial Cystitis/painful Bladder Syndrome 20 58
Interstitial Cystitis/bladder Pain Syndrome 20 58
Trigonitis 20 70
Ic/bps 20 58
Ic/pbs 20 58
Chronic Interstitial Cystitis 70
Pelvic Congestion Syndrome 70
Cystitis, Interstitial 44
Pelvic Pain Syndrome 20
Ulcerative Cystitis 12
Pelvic Pain 42
Pbs 20
Ic 20


Orphanet epidemiological data:

interstitial cystitis
Prevalence: 1-5/10000 (Finland),1-5/10000 (United States),1-9/1000000 (Finland); Age of onset: All ages; Age of death: normal life expectancy;


External Ids:

Disease Ontology 12 DOID:13949
KEGG 36 H01551
MeSH 44 D018856
NCIt 50 C27189
SNOMED-CT 67 197834003
ICD10 32 N30.1
MESH via Orphanet 45 D018856
ICD10 via Orphanet 33 N30.1
UMLS via Orphanet 71 C0282488 C0600040 C1720830 more
Orphanet 58 ORPHA37202
UMLS 70 C0152078 C0282488 C0600040 more

Summaries for Interstitial Cystitis

GARD : 20 Interstitial cystitis (IC) is a chronic condition that causes painful urinary symptoms. Symptoms and severity can vary. Some people may have only mild discomfort, or feel tenderness or pressure in the bladder or pelvis. Others may experience intense bladder pain, urgent or frequent needs to urinate, or pain during sexual intercourse. Symptoms may be constant, or they may come and go. Some people with IC have Hunner's ulcers (areas of inflammation on the bladder wall, identified by cytoscopy ). The exact cause of IC is not known. While the symptoms are similar to those of a bladder infection, IC is not an infection. It occurs more commonly in women, and in people with other chronic pain disorders such as irritable bowel syndrome or fibromyalgia. There is no cure for IC, but there are treatment options to help relieve the symptoms. No single treatment works for all people with IC. Often, people try different treatments or combinations of treatments before finding something that works. Treatment options may include lifestyle changes, oral or topical medications, bladder instillations, neuromodulation therapy, Botox injections in the bladder muscles, and surgery (in rare cases). Without treatment, IC can affect a person's sleep, daily activities, and social life.

MalaCards based summary : Interstitial Cystitis, also known as painful bladder syndrome, is related to urethral syndrome and fibromyalgia, and has symptoms including pain and other symptoms associated with female genital organs, mittelschmerz and unspecified symptom associated with female genital organs. An important gene associated with Interstitial Cystitis is NGF (Nerve Growth Factor), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Progesterone and Mepivacaine have been mentioned in the context of this disorder. Affiliated tissues include smooth muscle, endothelial and spinal cord, and related phenotypes are abnormality of the menstrual cycle and abnormality of the urethra

MedlinePlus : 42 Interstitial cystitis (IC) is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently. It is far more common in women than in men. The symptoms vary from person to person. Some people may have pain without urgency or frequency. Others have urgency and frequency without pain. Women's symptoms often get worse during their periods. They may also have pain with sexual intercourse. The cause of IC isn't known. There is no one test to tell if you have it. Doctors often run tests to rule out other possible causes of symptoms. There is no cure for IC, but treatments can help most people feel better. They include Distending, or inflating, the bladder Bathing the inside of the bladder with a drug solution Oral medicines Electrical nerve stimulation Physical therapy Lifestyle changes Bladder training In rare cases, surgery NIH: National Institute of Diabetes and Digestive and Kidney Diseases

KEGG : 36 Interstitial cystitis (IC), also referred to as bladder pain syndrome (BPS), is a chronic non-infectious inflammatory condition characterized by recurring discomfort, pain or pressure in the bladder and the surrounding pelvic region. IC/BPS most often affect females compared with males. The affected individuals experience urinary frequency and urgency. The duration of irritative symptoms associated with unpleasant sensation are longer than six weeks duration. At present, there are two major subtypes of IC/BPS: those with or without Hunner lesion, which are also known as ulcerative or non-ulcerative IC/BPS, respectively.

Wikipedia : 73 Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a type of chronic pain that... more...

Related Diseases for Interstitial Cystitis

Diseases in the Interstitial Cystitis family:

Chronic Interstitial Cystitis

Diseases related to Interstitial Cystitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 568)
# Related Disease Score Top Affiliating Genes
1 urethral syndrome 31.8 TAC1 P2RX3 NGF IL6 CXCL8
2 fibromyalgia 30.9 TACR1 NGF IL6 CXCL8 BDNF
3 acute cystitis 30.8 UPK3A UPK1A UMOD IL6 CXCL8
4 bacteriuria 30.7 UMOD IL6 CXCL8
5 pyelonephritis 30.6 UMOD IL6 CXCL8
6 pyuria 30.6 UPK3A IL6 CXCL8
7 chronic fatigue syndrome 30.6 IL6 CXCL8 CRHR1 BDNF
8 vesicoureteral reflux 1 30.5 UPK3A UPK1A UMOD CXCL8
9 radiation cystitis 30.4 UPK3A P2RX3
10 adenomyosis 30.4 NGF IL6 CXCL8 CDH1
11 rhinitis 30.4 NGF KNG1 IL6 CXCL8
12 hydronephrosis 30.4 UPK3A IL6 EGF CXCL8
13 algoneurodystrophy 30.3 TAC1 NGF KNG1
14 neuroma 30.3 TRPV1 NGF IL6
15 urinary tract obstruction 30.3 UPK3A UMOD HBEGF EGF CDH1
16 keratoconjunctivitis 30.2 NGF IL6 CXCL8
17 gastric ulcer 30.2 IL6 EGF CXCL8
18 acute kidney failure 30.1 UMOD KNG1 EGF
19 somatization disorder 30.1 TAC1 IL6
20 chronic cystitis 30.1 UPK3A UPK1A TRPV1 TAC1 P2RX3 NGF
21 radiculopathy 30.1 TAC1 IL6 CXCL8
22 neurotic disorder 30.1 NGF IL6 BDNF
23 mental depression 30.1 IL6 CRHR1 BDNF
24 reflex sympathetic dystrophy 30.0 TRPV1 TAC1 P2RX3 KNG1
25 adrenal gland pheochromocytoma 30.0 NGF BDNF
26 contact dermatitis 30.0 TACR1 NGF IL6 CXCL8
27 gastroenteritis 30.0 IL6 CXCL8 CDH1
28 spinal cord injury 30.0 IL6 CXCL8 BDNF
29 complex regional pain syndrome 30.0 TACR1 TAC1 IL6 CXCL8 CRHR1
30 mononeuropathy 29.9 TRPV1 TAC1 NGF
31 myofascial pain syndrome 29.8 TRPV1 TAC1 NGF KNG1 BDNF
32 substance abuse 29.8 IL6 CRHR1 BDNF
33 constipation 29.8 TRPV1 TACR1 TAC1 IL6 BDNF
34 nerve compression syndrome 29.8 TRPV1 TAC1 NGF IL6
35 panic disorder 29.7 TACR1 TAC1 CRHR2 CRHR1 BDNF
36 sleep apnea 29.7 TAC1 IL6 CXCL8 BDNF
37 irritable bowel syndrome 29.7 TRPV1 TAC1 NGF IL6 CXCL8 CRHR2
38 sleep disorder 29.7 TAC1 IL6 CXCL8 BDNF
39 pulmonary disease, chronic obstructive 29.7 TRPV1 TAC1 IL6 CXCL8
40 autonomic nervous system disease 29.7 TRPV1 TACR1 TAC1 NGF IL6
41 paine syndrome 29.6 TRPV1 TACR1 TAC1 P2RX3 NGF KNG1
42 migraine with or without aura 1 29.6 TRPV1 TACR1 TAC1 P2RX3 NGF KNG1
43 cystitis 29.6 UPK3A UPK1A UMOD TRPV1 TACR1 TAC1
44 burning mouth syndrome 29.6 TRPV1 TAC1 P2RX3 NGF IL6 CXCL8
45 causalgia 29.5 TRPV1 TACR1 TAC1 P2RX3 NGF
46 personality disorder 29.4 CRHR2 CRHR1 BDNF
47 neurogenic bladder 29.4 UPK3A UPK1A TRPV1 TACR1 TAC1 P2RX3
48 dermatitis, atopic 29.4 TACR1 TAC1 NGF IL6 CXCL8 BDNF
49 somatoform disorder 29.4 TRPV1 TACR1 TAC1 P2RX3 NGF IL6
50 mood disorder 29.3 TACR1 IL6 CRHR2 CRHR1 BDNF

Comorbidity relations with Interstitial Cystitis via Phenotypic Disease Network (PDN):

Acute Cystitis Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Interstitial Cystitis:

Diseases related to Interstitial Cystitis

Symptoms & Phenotypes for Interstitial Cystitis

Human phenotypes related to Interstitial Cystitis:

58 31 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the menstrual cycle 58 31 hallmark (90%) Very frequent (99-80%) HP:0000140
2 abnormality of the urethra 58 31 hallmark (90%) Very frequent (99-80%) HP:0000795
3 dyspareunia 58 31 hallmark (90%) Very frequent (99-80%) HP:0030016
4 pollakisuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0100515
5 urinary urgency 58 31 hallmark (90%) Very frequent (99-80%) HP:0000012
6 urinary bladder inflammation 58 31 hallmark (90%) Very frequent (99-80%) HP:0100577
7 pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0012531
8 nocturia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000017
9 abnormal labia morphology 31 hallmark (90%) HP:0000058
10 abnormal vagina morphology 31 occasional (7.5%) HP:0000142
11 abnormality of the bladder 58 Very frequent (99-80%)
12 abnormality of the genital system 58 Very frequent (99-80%)
13 abnormality of the vagina 58 Occasional (29-5%)
14 abnormality of the labia 58 Very frequent (99-80%)
15 functional abnormality of the bladder 58 Very frequent (99-80%)

UMLS symptoms related to Interstitial Cystitis:

pain and other symptoms associated with female genital organs; mittelschmerz; unspecified symptom associated with female genital organs; other specified symptoms associated with female genital organs; female genital pain and other symptoms

MGI Mouse Phenotypes related to Interstitial Cystitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 BDNF CRHR1 CRHR2 HBEGF IL6 KNG1
2 cardiovascular system MP:0005385 9.73 CDH1 CRHR1 CRHR2 FZD8 HBEGF IL6
3 integument MP:0010771 9.4 BDNF CDH1 CKAP4 EGF HBEGF IL6

Drugs & Therapeutics for Interstitial Cystitis

Drugs for Interstitial Cystitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
Polyestradiol phosphate Approved Phase 4 28014-46-2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
Nicotine Approved Phase 4 54-11-5 942 89594
Dienogest Approved Phase 4 65928-58-7
Drospirenone Approved Phase 4 67392-87-4 68873
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Acetaminophen Approved Phase 4 103-90-2 1983
Cycloserine Approved Phase 4 68-41-7 401 6234
Belladonna Approved, Experimental Phase 4
Tibolone Approved, Investigational Phase 4 5630-53-5
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
Norethindrone Approved Phase 4 68-22-4 6230
Ferrous fumarate Approved Phase 4 141-01-5
Hesperidin Approved, Investigational Phase 4 520-26-3 53477767
Polidocanol Approved Phase 4 9002-92-0
Ethanol Approved Phase 4 64-17-5 702
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
Sodium citrate Approved, Investigational Phase 4 68-04-2
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
Norepinephrine Approved Phase 4 51-41-2 439260
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Gestodene Investigational Phase 4 60282-87-3 3033968
37 Drospirenone and ethinyl estradiol combination Phase 4
38 Contraceptives, Oral, Combined Phase 4
39 Ulipristal acetate Phase 4 126784-99-4
40 Contraceptive Agents Phase 4
41 Contraceptives, Oral Phase 4
42 Hormone Antagonists Phase 4
43 Estradiol 3-benzoate Phase 4
44 Estradiol 17 beta-cypionate Phase 4
Medroxyprogesterone Phase 4 520-85-4 10631
46 Antineoplastic Agents, Hormonal Phase 4
47 Contraceptive Agents, Male Phase 4
48 Estrogens Phase 4
49 Central Nervous System Stimulants Phase 4
50 Nicotinic Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 434)
# Name Status NCT ID Phase Drugs
1 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
2 Botulinum A Toxin Intravesical Injections Versus Bladder Overdistension in the Treatment of Patients With Painful Bladder Syndrome: A Prospective Randomized Study Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
3 Efficacy of Peri-trigonal Onabotulinumtoxin Injections in the Treatment of Refractory Idiopathic Detrusor Overactivity (IDO): A Single-blind, Randomised Controlled Trial Comparing Peri-trigonal Injections vs Injection of the Bladder Body. Unknown status NCT02009540 Phase 4 Botulinum toxin injected to bladder body;Botulinum toxin injected into trigone
4 Comparison Between Blind and Ultrasound Guided Injection in Morton Neuroma Unknown status NCT03046108 Phase 4 blind injection of Mepivacaine;blind injection of Triamcinolone;guided injection of mepivacaine;guided injection of Triamcinolone
5 A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac Unknown status NCT01514175 Phase 4 IV Ibuprofen;IV Ketorolac
6 Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis Unknown status NCT02237131 Phase 4 Oral contraceptives cyclic;Oral contraceptives continuous
7 Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial. Unknown status NCT00844012 Phase 4 Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy);Cyclic OC (clormadinone acetate plus ethinil-estradiol)
8 Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain Unknown status NCT02213081 Phase 4 Ulipristal
9 The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4 Completed NCT02297100 Phase 4 Onabotulinumtoxin A
10 Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. Completed NCT01056042 Phase 4 intramuscular depot medroxyprogesterone acetate;ethinyl estradiol 30 micrograms, gestodene 75 micrograms
11 Effect of Nicotine on Chronic Pelvic Pain Completed NCT00440505 Phase 4 Placebo;Nicotine (5 mg);Nicotine (10 mg)
12 Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea? Completed NCT03124524 Phase 4 estradiol valerate/dienogest;ethinylestradiol and drospirenone
13 Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide). Completed NCT01769781 Phase 4 anastrazole;GnRH analog alone
14 Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial Completed NCT00194610 Phase 4 Botox
15 Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis Completed NCT01195116 Phase 4 Dexmedetomidine;Normal Saline
16 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
17 To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
18 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
19 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial) Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
20 Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients Completed NCT02534688 Phase 4 LNG-IUS;DMPA
21 Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis Completed NCT02427386 Phase 4 dynamized estrogen;placebo
22 The Effect of Intracervical Lidocaine Injection Versus Topical Lidocaine Gel on the Pain Experienced by Patients Undergoing Tenaculum Application to the Cervix at the Time of an Office Gynecologic Procedure Completed NCT01421641 Phase 4 Intracervical Lidocaine Injection;Topical Lidocaine Gel
23 Efficacy of Paraspinous Anesthetic Block in Patients With Chronic Pelvic Pain Non-Responsive to Pharmacological Treatment Completed NCT01635205 Phase 4
24 A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women Completed NCT00735852 Phase 4 Decapeptyl SR 11.25mg
25 Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis Completed NCT02480647 Phase 4 Levonorgestrel;Etonogestrel
26 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Completed NCT02298660 Phase 4 BOTOX
27 Interstitial Cystitis: Examination of the Central Autonomic Network Recruiting NCT03008382 Phase 4 Metoprolol Tartrate Oral Tablet;Placebo Oral Tablet
28 Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
29 A Prospective Cohort Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction Active, not recruiting NCT03199534 Phase 4 Botulinum toxin A 50u;Botulinum toxin A 100u;Botulinum toxin A 150u
30 Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome Not yet recruiting NCT04358497 Phase 4 Diosmin / Hesperidin;Ibuprofen 400 mg
31 IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial Not yet recruiting NCT04313972 Phase 4 low-dose naltrexone;Placebo oral tablet
32 Effectiveness 0f Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
33 Prospective Randomised Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of Painful Bladder Syndrome/ Interstitial Cystitis Terminated NCT04268810 Phase 4
34 Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia: A Randomized, Triple-Masked, Placebo-Controlled Study Terminated NCT00944151 Phase 4
35 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
36 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis Terminated NCT00086684 Phase 4 Pentosan polysulfate sodium 100 mg;Placebo;Pentosan polysulfate sodium 100 mg
37 Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
38 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
39 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
40 Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial. Terminated NCT00628355 Phase 4 lidocaine
41 Evaluating Duloxetine's Analgesic Effectiveness in Chronic Pelvic Pain Terminated NCT01451606 Phase 4 Duloxetine;Placebo
42 Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study Unknown status NCT02437175 Phase 3
43 The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period Unknown status NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
44 A Double-Blind, Randomized Study of Puncturing Versus Non-Puncturing Acupuncture for the Treatment of Interstitial Cystitis Symptoms Unknown status NCT00094874 Phase 3
45 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
46 Randomized Control Trial of Magnesium-Based Trigger Point Injections vs. Lidocaine-Only Trigger Point Injections for Relief of Chronic Myofascial Pelvic Pain Unknown status NCT02728037 Phase 3 lidocaine;magnesium sulfate, bicarbonate, dextrose.
47 Oral Gabapentin in Management of Chronic Pelvic Pain in Females: A Randomised Placebo-controlled Study. Unknown status NCT02918760 Phase 3 Gabapentin
48 Effects of Proxelan Somministration in Patients With Chronic Prostatitis Cat. IIa NIH: Pilot Study Unknown status NCT03629769 Phase 3 Proxelan
49 Evaluating the Efficacy of Intranasal Oxytocin Among Individuals With Persistent Pain Unknown status NCT02888574 Phase 2, Phase 3 Intranasal Oxytocin;Placebo
50 A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients Completed NCT00124306 Phase 3 Amitriptyline

Search NIH Clinical Center for Interstitial Cystitis

Cochrane evidence based reviews: cystitis, interstitial

Genetic Tests for Interstitial Cystitis

Anatomical Context for Interstitial Cystitis

MalaCards organs/tissues related to Interstitial Cystitis:

Smooth Muscle, Endothelial, Spinal Cord, Colon, Uterus, Prostate, Skin

Publications for Interstitial Cystitis

Articles related to Interstitial Cystitis:

(show top 50) (show all 3424)
# Title Authors PMID Year
Web-mediated counseling to counteract the emotional impact of COVID-19 for women with interstitial cystitis/bladder pain syndrome. 42 61
33660824 2021
Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. 61 42
32939046 2020
Effects of Etonogestrel implants on pelvic pain and menstrual flow in women suffering from adenomyosis or endometriosis: Results from a prospective, observational study. 42
33578561 2021
Acupuncture for chronic pelvic pain in patients with SPID: A protocol for systematic review and meta-analysis. 42
33530191 2021
Natural bladder filling alters resting brain function at multiple spatial scales: a proof-of-concept MAPP Network Neuroimaging Study. 42
33199816 2020
Efficacy and safety of extracorporeal shockwave therapy for the treatment of chronic non-bacterial prostatitis: A systematic review and meta-analysis. 42
33370372 2020
Treatment of acute dysmenorrhoea and pelvic pain syndrome of uterine origin with myometrial botulinum toxin injections under hysteroscopy: A pilot study. 61
33186771 2021
Single-cell transcriptomes of mouse bladder urothelium uncover novel cell type markers and urothelial differentiation characteristics. 61
33538002 2021
Application of hyaluronic acid in patients with interstitial cystitis. 61
33480631 2021
Factors associated with treatment outcomes after intravesical hyaluronic acid therapy in women with refractory interstitial cystitis: A prospective, multicenter study. 61
33784267 2021
Examination of pelvic floor muscle elasticity in patients with interstitial cystitis/bladder pain syndrome using real-time tissue elastography. 61
33740121 2021
The chicken or the egg: Longitudinal changes in pain and catastrophizing in women with interstitial cystitis/bladder pain syndrome. 61
33750522 2021
Interstitial Cystitis/Bladder Pain Syndrome as Referred Pain From Injured T12/L1 Nerves: Symptomatic Improvement With Resection of Ilioinguinal and Iliohypogastric Nerves. 61
33279610 2021
Commentary: Efficacy of Clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial. 61
33704539 2021
Re: Systemic Therapy for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC): Systematic Review of Published Trials in the Last 5 Years. 61
33257030 2021
Activation of MrgprA3 and MrgprC11 on bladder-innervating afferents induces peripheral and central hypersensitivity to bladder distension. 61
33727332 2021
Beneficial effect of Bletilla striata extract solution on zymosan-induced interstitial cystitis in rat. 61
33604897 2021
Selective blockade of transient receptor potential vanilloid 4 reduces cyclophosphamide-induced bladder pain in mice. 61
33737012 2021
Editorial Comment: Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial. 61
33284551 2021
Pentosan polysulfate maculopathy versus age-related macular degeneration: comparative assessment with multimodal imaging. 61
33722504 2021
Comparison of deep phenotyping features of UCPPS with and without Hunner lesion: A MAPP-II Research Network Study. 61
33604963 2021
[Endometriosis and chronic overlapping pain conditions]. 61
33576864 2021
Prevalence of autoimmune disorders among bladder pain syndrome patients' relatives. 61
32964777 2021
Autoimmunity to urothelial antigen causes bladder inflammation, pelvic pain, and voiding dysfunction: a novel animal model for Hunner-type interstitial cystitis. 61
33308017 2021
The association between exposure to domestic abuse in women and the development of syndromes indicating central nervous system sensitization: A retrospective cohort study using UK primary care records. 61
33559289 2021
Cannabinoids in Urology. Which Benign Conditions Might They Be Appropriate to Treat: A Systematic Review. 61
33129871 2021
Gabapentin reduces painful bladder hypersensitivity in rats with lipopolysaccharide-induced chronic cystitis. 61
33340266 2021
National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive Bladder. 61
31157717 2021
Long-term outcomes of ulcerative interstitial cystitis after complete transurethral resection with therapeutic hydrodistention. 61
32926313 2021
Does irritable bowel syndrome increase the risk of interstitial cystitis/bladder pain syndrome? A cohort study of long term follow-up. 61
33620539 2021
Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis. 61
33638677 2021
Improvement in Quality of Life with Pelvic Floor Muscle Training and Biofeedback in Patients with Painful Bladder Syndrome/Interstitial Cystitis. 61
33669734 2021
Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: A multicenter, randomized, double-blind, placebo-controlled, clinical study. 61
33580603 2021
Lifestyle and behavioral modifications made by patients with interstitial cystitis. 61
33542405 2021
Temporal Relationships between Pain, Mood and Urinary Symptoms in Urological Chronic Pelvic Pain Syndrome: A MAPP Network Study. 61
33535797 2021
Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment. 61
33432045 2021
Relationship between the frequency of electrocautery of Hunner lesions and changes in bladder capacity in patients with Hunner type interstitial cystitis. 61
33420263 2021
Bladder pain syndrome/interstitial cystitis in contemporary UK practice: Outcomes of phenotype-directed management. 61
32869495 2021
Shionone alleviates NLRP3 inflammasome mediated pyroptosis in interstitial cystitis injury. 61
33223465 2021
Clinical characterization of interstitial cystitis/bladder pain syndrome in women based on the presence or absence of Hunner lesions and glomerulations. 61
32830459 2021
MicroRNA-495 alleviates ulcerative interstitial cystitis via inactivating the JAK-STAT signaling pathway by inhibiting JAK3. 61
33416962 2021
Women's Experiences of Interstitial Cystitis/Painful Bladder Syndrome. 61
33514302 2021
A comparison of two intravesical bladder instillations for interstitial cystitis/bladder pain syndrome. 61
33248378 2021
Adenosine A2A Receptor Agonist Polydeoxyribonucleotide Alleviates Interstitial Cystitis-Induced Voiding Dysfunction by Suppressing Inflammation and Apoptosis in Rats. 61
33623409 2021
Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes among Patients with Interstitial Cystitis/Bladder Pain Syndrome: An Investigation of the European Society for the Study of Interstitial Cystitis Histopathological Classification. 61
32856961 2021
Managing Interstitial Cystitis/Bladder Pain Syndrome in Older Adults. 61
33094445 2021
Efficacy of Clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial. 61
33452887 2021
Comment on "Presenting an Atlas of Hunner lesions in interstitial cystitis which can be identified with office cystoscopy" by Ronstrom and Lai, Neurourology and Urodynamics 2020;1-7. https://doi.org/10.1002/nau.24500. 61
33150601 2021
Comparison of Intravesical Hyaluronic Acid, Chondroitin Sulfate and Combination of Hyaluronic Acid-Chondroitin Sulfate Therapies in Animal Model of Interstitial Cystitis. 61
33504136 2021
Biomaterial-assisted drug delivery for interstitial cystitis/bladder pain syndrome treatment. 61
33179709 2021

Variations for Interstitial Cystitis

Expression for Interstitial Cystitis

Search GEO for disease gene expression data for Interstitial Cystitis.

Pathways for Interstitial Cystitis

Pathways related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
5 12.46 KNG1 IL6 FZD8 EGF CXCL8 CDH1
6 12.25 TACR1 P2RX3 NGF EGF
Show member pathways
Show member pathways
Show member pathways
10 11.95 IL6 FZD8 EGF CDH1
11 11.75 IL6 HBEGF EGF
12 11.73 CXCL8 CRHR2 CRHR1
13 11.65 NGF EGF BDNF
14 11.54 TACR1 IL6 CXCL8 BDNF
15 11.51 IL6 HBEGF CXCL8
16 11.47 IL6 EGF CXCL8
19 10.75 EGF BDNF
21 10.32 TACR1 TAC1
22 10.3 CRHR2 CRHR1

GO Terms for Interstitial Cystitis

Cellular components related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.13 UPK3A UPK1A UMOD TRPV1 TACR1 P2RX3
2 integral component of plasma membrane GO:0005887 9.91 UPK1A TRPV1 TACR1 P2RX3 HBEGF CRHR2
3 extracellular space GO:0005615 9.91 UMOD TAC1 NGF KNG1 IL6 HBEGF
4 extracellular region GO:0005576 9.85 UMOD TAC1 NGF KNG1 IL6 HBEGF
5 plasma membrane GO:0005886 9.5 UPK3A UPK1A UMOD TRPV1 TACR1 TAC1
6 apical plasma membrane urothelial plaque GO:0120001 8.96 UPK3A UPK1A

Biological processes related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.02 TACR1 TAC1 KNG1 FZD8 CXCL8 CRHR2
2 signal transduction GO:0007165 9.85 TACR1 P2RX3 IL6 HBEGF FZD8 EGF
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.75 IL6 HBEGF EGF
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 NGF IL6 BDNF
5 modulation of chemical synaptic transmission GO:0050804 9.69 P2RX3 NGF BDNF
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.62 TRPV1 TACR1 TAC1 KNG1
7 positive regulation of acute inflammatory response GO:0002675 9.58 TAC1 IL6
8 positive regulation of epidermal growth factor-activated receptor activity GO:0045741 9.57 HBEGF EGF
9 behavioral response to pain GO:0048266 9.55 TRPV1 P2RX3
10 nerve growth factor signaling pathway GO:0038180 9.54 NGF BDNF
11 negative regulation of heart rate GO:0010459 9.52 TRPV1 TAC1
12 regulation of protein localization to cell surface GO:2000008 9.49 EGF BDNF
13 positive regulation of collateral sprouting GO:0048672 9.46 NGF BDNF
14 tachykinin receptor signaling pathway GO:0007217 9.43 TACR1 TAC1
15 urinary bladder smooth muscle contraction GO:0014832 9.4 TRPV1 P2RX3
16 cellular response to corticotropin-releasing hormone stimulus GO:0071376 9.37 CRHR2 CRHR1
17 detection of abiotic stimulus GO:0009582 9.26 TACR1 TAC1
18 inflammatory response GO:0006954 9.17 UMOD TRPV1 TACR1 TAC1 KNG1 IL6
19 response to pain GO:0048265 9.13 TRPV1 TACR1 TAC1

Molecular functions related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.62 TRPV1 FZD8 CRHR2 CRHR1
2 nerve growth factor receptor binding GO:0005163 9.26 NGF BDNF
3 corticotropin-releasing hormone receptor activity GO:0043404 9.16 CRHR2 CRHR1
4 growth factor activity GO:0008083 9.02 NGF IL6 HBEGF EGF BDNF
5 corticotrophin-releasing factor receptor activity GO:0015056 8.96 CRHR2 CRHR1

Sources for Interstitial Cystitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....